We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Role of PAM4 in the Management of Pancreatic Cancer: Diagnosis, Radioimmunodetection, and Radioimmunotherapy.
- Authors
Suxia Han; Guihua Jin; Lijuan Wang; Meng Li; Chenchen He; Xijing Guo; Qing Zhu
- Abstract
PAM4, a new monoclonal antibody (MAb) known as clivatuzumab, is highly reactive with pancreatic cancer and precursor lesions. It is absent from the normal tissues and has limited reactivity with nonpancreatic cancer. The detailed characteristic of the PAM4 epitope is unknown but recent studies have shown that it is dependent on MUC1 glycosylation status. The limited PAM4 expression pattern makes it an attractive candidate for management of pancreatic adenocarcinoma. In addition, PAM4 is a serum biomarker for diagnosis of pancreatic cancer. Several different radiolabeled immunodiagnostic and immunotherapeutic agents of PAM4 have been developed and some are being evaluated in preclinical and/or clinical studies. The review will focus on PAM4 and its potential utility for the diagnosis, radioimmunodetection, and radioimmunotherapy of pancreatic cancer.
- Subjects
PANCREATIC cancer diagnosis; RADIOIMMUNOTHERAPY; MONOCLONAL antibodies; IMMUNODIAGNOSIS; COMPUTED tomography; MAGNETIC resonance imaging; POSITRON emission tomography
- Publication
Journal of Immunology Research, 2014, p1
- ISSN
2314-8861
- Publication type
Article
- DOI
10.1155/2014/268479